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Red Blood Cell Distribution Width (RDW) represents the 
coefficient of variation of the red blood cell volume distri-
bution width and can be considered an index of heterogene-
ity, the equivalent of anysocitosis observed in the peripheral 
blood smear. It is routinely reported as part of the complete 
blood count, but its use is generally restricted to narrowing 
the differential diagnosis of anaemia. Higher RDW is asso-
ciated with mortality in patients with heart failure, stable 
coronary artery disease, acute coronary syndromes (ACS), 
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Abstract
Background: Red Cell Distribution Width (RDW) prognostic value in patients with Acute Coronary Syndrome (ACS) 
has been well validated whereas that of Platelet Distribution Width (PDW) is less well known.
Objectives: Investigate the incremental prognostic value, on top of GRACE risk score, of a new variable resulting from 
the combination of RDW and PDW.
Methods: Consecutive patients with ACS. Complete blood count, with RDW and PDW, was obtained. Primary 
endpoint was one-year all-cause mortality and Cox regression models were used to measure the influence of RDW and 
PDW on patients’ survival time. A new combination categorical variable (RDW/PDW) was created with both discretized 
RDW and PDW and logistic regression models were used. Predictive value and discriminative ability of the model with 
GRACE risk score alone and of the model with inclusion of RDW/PDW was assessed.
Results: We included 787 patients. Hospital and one-year mortality rates were 5.1% and 7.8%, respectively. Both 
continuous RDW and PDW were independent predictors of death. The best cut-off for RDW was 13.9%, and 14.5% for 
PDW. Inclusion of RDW/PDW in a model with GRACE risk score improved the AUC from 0.81 (95% CI 0.75–0.86) to 
0.84 (95% CI 0.79–0.90) (p=0.024) with an improvement in total NRI (56%) and IDI (0.048).
Conclusions: Simple markers such as RDW and PDW can be useful in risk stratification of death after ACS. Combining 
both markers with GRACE risk score improved the predictive value for all-cause mortality and reduced the estimated 
risk of those who did not die.
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in patients undergoing percutaneous coronary revasculari-
zation and also in the general population.1–7
Platelet Distribution Width (PDW) represents a similar 
measurement applied to platelets. Platelets have been 
implicated in the pathogenesis of cardiovascular disorders, 
including atherosclerosis and its complications, such as 
ACS.8,9 However, the evidence for mortality prediction is 
scarce when compared to RDW, with very few biblio-
graphic references on the subject.
The Global Registry of Acute Coronary Events 
(GRACE) risk score is a validated and established score for 
risk stratification of patients with ACS, obtained from a 
multicentre registry.10 This score is based on several clini-
cal and laboratorial variables and is used worldwide with a 
very good predictive value.
We sought to investigate the predictive value of each 
haematological marker individually, as well as the poten-
tial incremental prognostic value, on top of GRACE risk 
score, of a new variable that resulted from a combination 
of both markers (RDW/PDW), because the prognostic 
information from both variables might potentiate prognos-
tic predictiveness.
Population and methods
This is a cohort study of consecutive patients admitted to 
our Intensive Care Unit with ACS (with and without 
ST-segment elevation) during the years 2008 through 2010. 
Data was collected prospectively and recorded on a com-
puter database of ACS patients admitted to our institution’s 
Intensive Care Unit. Inclusion criteria were a history of 
chest pain at rest or other symptoms suggestive of an ACS, 
with the most recent episode occurring within 24 hours of 
admission. This could be associated with new or presumed 
new significant ST-segment – T wave changes/new left 
bundle branch block or elevated levels of biomarkers of 
myocardial damage (cardiac troponin I and creatinine 
kinase). Myocardial infarction was defined by a rise and/or 
fall of cardiac troponin I with at least one value above 0.06 
ng/mL. We evaluated demographic characteristics of the 
patients, risk factors for coronary artery disease, previous 
cardiac history and vital signs on admission as well as in-
hospital treatment. Blood samples were obtained on admis-
sion. We used automated laboratory equipment (Beckman 
Coulter Automated CBC Analyzer – LH 750™) for haema-
tological evaluation. Normal reference range for RDW in 
our laboratory is 11.5%–15.5% and for PDW is 9.0%–
17.0%. Patients with increased RDW and PDW were 
defined by a cut-off obtained with the statistical analysis 
described below.
Hypertension, diabetes and hyperlipidemia were defined 
as either previously known or on specific therapy. Patients 
that smoked during the previous six months were classified 
as smokers and were self-reported. Estimated glomerular 
filtration rate (GFR) was calculated according to the 
Cockcroft-Gault formula.11 For each patient, a numerical 
classification according to the previously described 
GRACE risk score was calculated from the initial clinical 
history, electrocardiogram and laboratory values collected 
at admission.10
Follow-up was obtained for every patient that survived 
to discharge by reviewing the medical records and/or by 
telephone interview with the patient or family members at 
30 days and one year after admission. Follow-up informa-
tion was obtained in 99.8% of the patients. The study pri-
mary endpoint was all-cause mortality at the one-year 
follow-up.
The study complies with the Declaration of Helsinki and 
informed consent was obtained from all the subjects.
Statistical analysis
Continuous variables were presented as mean or median, 
standard deviation or inter-quartile range (25th–75th per-
centile), as required. Normality and homogeneity of vari-
ances were tested by Kolmogorov-Smirnov test and Levene 
test, respectively. Groups were compared with ANOVA or 
with the non-parametric Kruskal-Wallis test whenever 
appropriate. Categorical data were presented as frequencies 
and percentages and Pearson’s Chi-squared test or Fisher’s 
exact test, were used.
The primary endpoint was one-year all-cause mortality 
and univariable and multivariable Cox proportional haz-
ards regression models were used to measure the individual 
influence of RDW and PDW on the survival time. To test 
for proportional hazards assumption, Schoenfeld’s global 
test was used. A global measure of concordance was also 
calculated.
Moreover, considering death within one-year follow-up, 
the best cut-off points of both parameters (RDW and PDW) 
were selected by maximizing the sum of sensitivity and 
specificity. A code was given for each variable: 0 = below 
cut-off; 1 = above or equal to cut-off. A new categorical 
variable RDW/PDW with three groups was obtained by 
summing these two binary variables. Two logistic regres-
sion models were then fitted to the data, with GRACE risk 
score alone and with the new variable RDW/PDW included. 
Predictive and discriminative abilities were assessed by the 
Hosmer-Lemeshow goodness of fit test and by the area 
under the Receiver Operating Characteristic curve (AUC), 
respectively. To compare the AUC from each of these mod-
els, the method described by DeLong et al. was used.12 The 
Akaike Information Criterion was also used to compare the 
two models.
The incremental predictive value resulting from adding 
RDW/PDW variable to GRACE risk score was analysed 
with Continuous Net Reclassification Improvement (NRI) 
and Integrated Discrimination Improvement (IDI). The net 
proportion of patients who died (with events) with higher 
probabilities of death (NRIevents) and of patients who did not 
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die (without events) with lower probabilities of death 
(NRInonevents), were calculated considering both models. 
The NRI is the sum of NRIevents and NRInonevents and quanti-
fies the correctness of upward and downward movement of 
predicted probabilities as a result of adding a new marker.13 
The IDI is a measure of the improvement in prediction and 
may be viewed as the difference between improvement in 
average sensitivity and average 1-specificity.13
For all comparisons, a p value < 0.05 was considered 
statistically significant. When appropriate, 95% confidence 
intervals (CI) were calculated.
Statistical analysis was carried out using the IBM SPSS 
Statistics, Version 21.0 (IBM Corp., North Castle, New 
York, USA) and the R software.14
Results
A total of 787 consecutive patients were included in the 
study, with a mean age of 64 ± 13 years, 70% males. The 
majority of the patients were admitted with an ST-segment 
elevation acute myocardial infarction (STEMI) (62%). In 
our sample, median GRACE risk score was 139 (P25: 114–
P75: 161). The in-hospital, 30-day and one-year mortality 
rates were 5.1%, 5.8% and 7.8%, respectively. RDW corre-
lated with haemoglobin values (r=−0.34, p<0.001) and 
PDW correlated with platelet numbers (r=−0.15, p<0.001). 
Patients with Non-STEMI or unstable angina were elderly, 
had more risk factors for coronary artery disease (except for 
smoking), more frequent previous cardiac history and medi-
cations compared to patients with STEMI (Supplemental 
Table). Patients with STEMI or non-STEMI had higher 
heart rate, systolic blood pressure, GRACE risk score and 
lower GFR compared to patients with unstable angina. No 
differences were found in haematological parameters 
according to admission diagnosis, with the exception of 
PDW. There were also no statistically significant differences 
in outcome, although there were no deaths in the unstable 
angina group.
The concordance index obtained for the Cox regression 
model with only the continuous RDW as an independent 
variable was 0.67 (95% CI: 0.60–0.74). For PDW, the 
obtained concordance was 0.63 (95% CI: 0.56–0.70). In 
the univariable analysis, age, gender, smoking, diabetes, 
heart rate, systolic blood pressure, angiotensin-converting 
enzyme inhibitors and beta-blockers use, Killip class, esti-
mated glomerular filtration rate, PCI, RDW and PDW 
were significant predictors of outcome. In the multiple 
Cox proportional-hazards regression model, RDW and 
PDW remained as independent predictors of all-cause 
mortality after adjusting for age, diabetes, heart rate, sys-
tolic blood pressure, angiotensin-converting enzyme 
inhibitor and beta-blocker (Table 1). Proportional hazards 
assumption was met (p=0.277) and the global concordance 
of the final model was 0.83 (95% CI: 0.75–0.90). Anaemia 
is also an important predictor of mortality in ACS. In our 
study, in univariable analysis, anaemia showed an OR of 
2.79 (95% CI 1.64–4.73, p<0.001) for all-cause mortality. 
Since anaemia could influence outcome and RDW values, 
we checked it in multivariable analysis. RDW remained as 
an independent predictor of outcome after adjustment for 
the presence of anaemia (OR 1.22, 95% CI 1.05–1.42, 
p=0.010) or after adjustment for haemoglobin values as a 
continuous variable (OR 1.22, 95% CI 1.04–1.43, 
p=0.013). This confirmed that although important for out-
come, RDW does not lose its predictive ability after adjust-
ment for the presence of anaemia.
Before studying how much RDW and PDW add to the 
predictive and discriminative ability of GRACE risk score 
and, due to the known usefulness of cut-off points in clini-
cal practice, RDW and PDW were discretized by 
Table 1. Univariable and multivariable Cox proportional hazards regression analysis.
Variable Univariable analysis p value Multivariable analysis p value
HR (95% CI) HR (95% CI)
Age (per 10 years increase) 2.04 (1.63–2.57) <0.001 1.98 (1.55–2.52) <0.001
Male gender 0.43 (0.26–0.71) 0.001 – –
Smoking 0.42 (0.23–0.77) 0.005 – –
Diabetes 2.22 (1.33–3.69) 0.002 1.70 (1.00–2.90) 0.051
Heart rate (per 10 bpm increase) 1.30 (1,15–1.48) <0.001 1.26 (1.22–1.42) <0.001
SBP (per 10 mmHg increase) 0.85 (0.77-0.93) 0.001 0.80 (0.72–0.88) <0.001
ACEI 0.40 (0.23–0.71) 0.002 0.51 (0.28–0.95) 0.033
Beta-blocker 0.39 (0.23–0.68) 0.001 0.45 (0.25–0.81) 0.008
Killip class > 1 3.23 (1.95–5.37) <0.001 – –
eGFR < 60 3.33 (2.00–5.55) <0.001 – –
PCI 0.54 (0.31–0.92) 0.022 – –
RDW 1.24 (1.12–1.37) <0.001 1.17 (1.03–1.32) 0.012
PDW 1.20 (1.08–1.35) 0.001 1.14 (1.02–1.28) 0.022
ACEI: angiotensin converting enzyme inhibitor; PCI: percutaneous coronary intervention; eGFR: estimated glomerular filtration rate; SBP: systolic 
blood pressure.
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maximizing the sum of sensitivity and specificity. RDW 
had an AUC of 0.672 (95% CI 0.603–0.741) and PDW an 
AUC of 0.635 (95% CI 0.567–0.703). The best cut-off for 
RDW was 13.9%, with a sensitivity of 62.3% (95% CI: 
49.0–74.4) and a specificity of 62.0% (95% CI: 58.3–
65.5); the best cut-off for PDW was 14.5%, with a sensitiv-
ity of 73.8% (95% CI: 60.9–84.2) and a specificity of 
49.4% (95% CI: 45.8–53.2). A new variable RDW/PDW 
was then constructed as explained above. Patients with 
increases in both RDW and PDW (Group 2) were older 
and less often males. No significant associations were 
observed for coronary artery disease, diabetes, smoking, 
previous history, other initial presentation data and treat-
ment (Table 2).
We built prediction models with GRACE risk score 
alone and after including the new RDW/PDW variable. 
AUC increased significantly after the inclusion of this vari-
able in the model, although with a decrease in the goodness 
of fit (Figure 1, Table 3). However, Akaike Information 
Criterion also improved with the lowest value attained by 
the model with RDW/PDW variable, indicating a better 
model. Overall, the inclusion of RDW/PDW in a model 
with GRACE risk score was associated with a NRI of 56%, 
suggesting correct upward and downward movement of 
predicted probabilities of death. However, these move-
ments occurred more effectively in the non-events group. 
In fact, the new model reduced the estimated probability of 
death in 58% of those without events. That is, the new 
model may better identify those patients who did not die. 
The IDI again showed that the model diagnostic perfor-
mance was significantly improved by adding RDW/PDW 
to the GRACE risk score (IDI = 0.048) (Table 3).
Discussion
RDW reflects variability in circulating red blood cell size. 
It is based on the width of red blood cell volume distribu-
tion curve, with larger values indicating greater variability. 
Conditions of ineffective red cell production (such as iron 
deficiency, B12 of folate deficiency, and haemoglobinopa-
thies), increase red cell destruction (such as haemolysis), 
and blood transfusion increase RDW.
RDW is an independent predictor of all-cause mortality 
in different patient populations and it gives valuable infor-
mation for short-term risk stratification of ACS.1–7 RDW is 
also an independent predictor of major bleeding in patients 
with non-ST-segment elevation myocardial infarction.15 
Anaemia has been shown to be a powerful and independent 
predictor of adverse cardiovascular outcomes.16–18 
Adjustment for multiple potential confounders (including 
anaemia) attenuated, but did not eliminate, the association 
between higher RDW levels and the adverse clinical out-
comes.16 In our sample, the same was observed. A study 
analysed both baseline and discharge RDW in patients with 
acute myocardial infarction.19 They concluded that an 
increase in RDW during hospitalization shifted patients to 
a higher level of risk. On the contrary, decreasing RDW had 
a favourable outcome. Thus RDW is a dynamic marker of 
risk. RDW levels were significantly increased in patients 
with inadequate ST-segment resolution after primary PCI 
and baseline levels predicted no-reflow.20 It was also an 
independent predictor of 6-month cardiovascular mortality, 
even after adjustment for multiple confounders including 
anaemia.20
The mechanisms by which elevated values of RDW are 
associated with adverse outcome in patients with cardio-
vascular disease have yet to be fully clarified but are prob-
ably multifactorial. In the context of ACS, we have an 
increase in inflammatory cytokines, oxidative stress, acti-
vation of neurohumoral pathways and adrenergic activa-
tion, all implicated in adverse outcome after ACS, and all 
these mechanisms seem to be involved in bone marrow 
response and erythroid cell poiesis.21–32 In ACS, there is 
usually an infarct-related inflammatory response with 
excess cytokine production. Proinflammatory cytokines 
have been found to inhibit erythropoietin-induced erythro-
cyte maturation, allowing juvenile erythrocytes to enter 
into circulation and leading to an increase in size heteroge-
neity.27,28 Plasma erythropoietin levels increase in the early 
phase of acute myocardial infarction independently of hae-
moglobin levels.29 Oxidative stress also causes damage 
which reduces cell survival, and it enhances the release of 
juvenile erythrocytes to circulation.30 Activation of neuro-
humoral pathways with elevated circulating levels of neu-
rohumoral mediators can affect erythropoiesis.31,32
Platelet hyper-reactivity and local platelet activation 
have been suggested to play a causal role in ACS.33 
Platelet size reflects platelet activity, with larger platelets 
being metabolically and enzymatically more active than 
small platelets. Large platelets are denser, aggregate 
more rapidly upon collagen challenge, produce larger 
amounts of thromboxane A2, release more serotonin and 
β-thromboglobulin, and express more Ib and IIb/IIIa gly-
coproteins.34,35 Platelet activation causes morphologic 
changes, from discoid to spherical shape and pseudopodia 
formation with increased PDW.36,37 Patients with ACS 
(compared to control patients and patients with stable 
angina) have raised platelet volume indices.8 The increase 
in platelet consumption at the site of coronary atheroscle-
rotic plaque causes larger platelets to be released from the 
bone marrow and the increase persists even after hospital 
discharge.8 Erythropoietin and thrombopoietin have con-
siderable structural homology and erythropoietin may also 
increase platelet reactivity.38
Several studies showed that Mean Platelet Volume 
(MPV) is an independent risk factor in myocardial infarc-
tion with aggravated clinical outcomes and higher mortal-
ity.39,40 In a meta-analysis, an increased MPV was associated 
with acute myocardial infarction, mortality following myo-
cardial infarction, and restenosis following PCI.41 It is also 
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associated with no ST-segment resolution after treatment 
with streptokinase and no-reflow after primary PCI.42,43 In 
fact, large platelets are younger platelets and this is a sign 
of increased platelet turnover. In diabetic patients, MPV is 
a strong predictor of the thromboxane B2 recovery slope 
after acetylsalicylic acid administration, suggesting that the 
diabetic milieu may account for the faster de novo synthesis 
of cyclooxygenase-1 in the bone marrow progenitors or 
their accelerated turnover, increasing risk.44
Although MPV has been extensively evaluated, novel 
platelet indices such as PDW have been less well investi-
gated as platelet activation markers. PDW is significantly 
increased in patients with STEMI and is an independent 
predictor of STEMI.45 More recently, it was demonstrated 
Table 2. Clinical characteristics by each RDW/PDW group.
Group 0 Group 1 Group 2 p value
 n=243 n=362 n=182  
Age (years) 61 (13)  64 (13)  66 (14) 0.001†
Male gender (%) 77.0 67.1 65.4 0.012
Risk factors (%)  
 Hypertension 63.0 66.9 70.9 0.228
 Hyperlipidemia 53.9 49.7 51.1 0.599
 Diabetes 23.9 23.2 27.5 0.535
 Smoking 38.3 40.9 35.7 0.492
Previous history (%)  
 Myocardial infarction 16.0 19.1 20.3 0.485
 PCI 11.1 13.5 11.0 0.571
 CABG 4.9 4.4 7.7 0.262
 Stroke / TIA 3.7 8.3 6.6 0.080
Initial presentation  
 STEMI n (%) 56.8 63.8 63.2 0.191
 Killip class >1 (%) 18.9 19.3 21.4 0.793
 HR (bpm) 78 (66–90)  80 (65–88)  80 (66–94) 0.302
 SBP (mmHg) 130 (117–150) 131 (117–153) 132 (120–157) 0.621
Laboratory data  
 eGFR < 60 ml/min/1.73m2 (%) 32.5 28.7 34.1 0.383
 Haemoglobin (g/dL) 13.9 (1.6) 13.6 (1.8) 13.2 (2.1) <0.001
 Anemia (%) 18.9 27.9 38.5 <0.001
 RDW 13.0 (12.7–13.4) 13.5 (13.0–14.0) 14.4 (14.0–15.1) <0.001‡
 PDW 12.5 (11.7–13.4) 15.6 (13.28–16.6) 16.5 (16.2–17.2 <0.001‡
Platelets (x103) 214 (185–248) 203 (169–242) 210 (168–256) 0.055
GRACE risk score 140 (117.0–159.0) 137 (112.0–160.0) 139.5 (114.8–162.5) 0.544
LVEF < 35% (%) 3.3 7.2 7.1 0.106
Treatment (%)  
 ASA 99.2 98.6 98.9 0.817
 Clopidogrel 96.7 96.4 96.2 0.953
 ACEI 87.2 86.2 86.8 0.930
 Beta-blocker 86.9 84.5 84.6 0.870
 Statin 93.8 94.8 91.2 0.276
 PCI 80.2 78.7 76.9 0.709
 CABG 2.1 1.1 0.5 0.362
All-cause mortality (%)  
In-hospital mortality 1.6 4.1 11.5 <0.001
30-day mortality 2.9 4.1 13.2 <0.001
One-year mortality 3.3 6.4 16.5 <0.001
Continuous variables are presented as mean (SD) or median (P25–P75), as appropriate.
CABG: coronary artery bypass grafting; CK: creatinine kinase; ASA: acetil-salicilic acid; ACEI: angiotensin converting enzyme inhibitor; eGFR: esti-
mated glomerular filtration rate; TIA: transient ischemic attack; HR: heart rate; SBP: systolic blood pressure; LVEF: left ventricular ejection fraction.
Multiple comparisons:
†Group 0 vs. Group 2, p<0.001; Group 1 vs. Group 2, p=0.044.
‡Group 0 vs. Group 1, p <0.001; Group 0 vs. Group 2, p<0.001; Group 1 vs. Group 2, p<0.001.
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that admission PDW correlated to platelet activation, no-
reflow, in-hospital and long-term major acute coronary 
events (in-stent thrombosis, non-fatal myocardial infarc-
tion, coronary revascularization and in-hospital mortality) 
amongst patients with STEMI undergoing thrombolysis or 
primary PCI.35,42,45,46 The prognostic value of PDW was 
even stronger than that previously reported for MPV.
Currently, automated cell counters enable routine avail-
ability of an extended panel of platelet volume indices 
beyond MPV (including PDW) routinely available in most 
clinical laboratories. RDW is also widely available to clini-
cians as part of the complete blood count and, therefore, 
incurs no additional costs, in contrast to other novel mark-
ers of cardiovascular risk.
Our results in medium-term follow-up in a population 
with the whole spectrum of ACS confirmed the independ-
ent association between RDW and PDW and survival time, 
after adjustment for relevant variables. They also showed 
some benefit in risk stratification after the inclusion in a 
model with GRACE risk score.
To better assess the improvement in outcome risk pre-
diction we did a prediction/discrimination-oriented study 
which showed a significant AUC increase after including 
RDW/PDW in the model with GRACE risk score alone. 
The Akaike Information Criterion, a measure that consid-
ers both the goodness of fit and complexity of the model, 
also showed that this last model was the best. Considering 
the other new statistical metrics, recently proposed to 
quantify the degree of correct reclassification, the inclu-
sion of RDW/PDW in a model with GRACE risk score 
was associated with a NRI of 56%. However, the new 
model identifies better those who do not have events than 
those who do. We also have found an IDI compatible with 
a favourable result after adding RDW/PDW to the GRACE 
risk score. Our results showed that adding RDW/PDW to a 
model with GRACE risk score could mainly better identify 
patients at low risk. The identification of ‘truly low-risk’ 
patients, instead of focusing mainly on identification of 
high-risk patients, may allow a better selection of patients 
avoiding unnecessary interventions that might increase 
costs as well as the risk of intervention-related adverse 
events, such as intensive anti-platelet or anti-thrombotic 
therapy. It can also help in the selection of patients for 
early discharge.
Limitations
This is a single-centre study which might limit the conclu-
sions. It is also a retrospective and non-randomized study. 
It might not be applicable to other populations with differ-
ent baseline characteristics. Particularly, our population has 
a predominance of STEMI patients, explained by the fact 
that we are a tertiary centre which receives many patients, 
from other hospitals for primary percutaneous coronary 
intervention. However, this does not reflect the distribution 
in other cohort studies of ACS and some caution should be 
taken when extending our results to other cohorts.
There might be some confounding factors such as eryth-
ropoietin levels, iron, folic acid and vitamin B12 that were 
not measured. Other known or unknown comorbidities that 
Figure 1. ROC curve analysis comparing the GRACE risk 
score and the new model with the inclusion of RDW/PDW 
(p=0.024).
Table 3. Statistics for model improvement with the addition of 
RDW/PDW.
Events, n (%)  61 (7.8)
Nonevents, n (%) 726 (92.2)
Continuous NRI (%)  
 cNRIevents  −2 (−27–24)
 cNRInonevents  58 (30–83)
 cNRI  56 (51–65)
IDI statistics  
 IDIevents 0.044
 IDInonevents 0.004
 IDI 0.048 (0.022–0.073)
AIC  
 GRACE risk score 359.47
 GRACE + RDW/PDW 341.25
AUC  
 GRACE risk score 0.81 (0.75–0.86)
 GRACE + RDW/PDW 0.84 (0.79–0.90)
 Difference (p value) 0.024
Goodness of fit (GRACE risk score)* 0.559
Goodness of fit (GRACE + RDW/PDW)* 0.052
95% confidence intervals are shown in parenthesis.
*Hosmer-Lemeshow goodness of fit test p value.
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could influence RDW and PDW were not specifically ana-
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